AUDRINA 21 TABLET

देश: कनाडा

भाषा: अंग्रेज़ी

स्रोत: Health Canada

इसे खरीदें

सक्रिय संघटक:

LEVONORGESTREL; ETHINYL ESTRADIOL

थमां उपलब्ध:

JAMP PHARMA CORPORATION

ए.टी.सी कोड:

G03AA07

INN (इंटरनेशनल नाम):

LEVONORGESTREL AND ESTROGEN

डोज़:

100MCG; 20MCG

फार्मास्यूटिकल फॉर्म:

TABLET

रचना:

LEVONORGESTREL 100MCG; ETHINYL ESTRADIOL 20MCG

प्रशासन का मार्ग:

ORAL

पैकेज में यूनिट:

15G/50G

प्रिस्क्रिप्शन प्रकार:

Prescription

उत्पाद समीक्षा:

Active ingredient group (AIG) number: 0220415002; AHFS:

प्राधिकरण का दर्जा:

APPROVED

प्राधिकरण की तारीख:

2022-10-21

उत्पाद विशेषताएं

                                PRODUCT MONOGRAPH
Pr AUDRINA
TM 21 AND
Pr AUDRINA
TM 28
Levonorgestrel and Ethinyl Estradiol Tablets, USP
100 mcg levonorgestrel and 20 mcg ethinyl estradiol tablets
Oral Contraceptive
JAMP Pharma Corporation
1310, rue Nobel
Boucherville, Quebec
J4B 5H3
DATE OF PREPARATION:
October 20, 2022
SUBMISSION CONTROL NO: 232154
_Page 2 of 55_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..................................................... 3
SUMMARY PRODUCT INFORMATION
....................................................................3
INDICATIONS AND CLINICAL
USE..........................................................................3
CONTRAINDICATIONS..............................................................................................3
WARNINGS AND PRECAUTIONS
.............................................................................4
ADVERSE REACTIONS
............................................................................................
14
DRUG INTERACTIONS
............................................................................................
21
DOSAGE AND
ADMINISTRATION..........................................................................
28
OVERDOSAGE..........................................................................................................
32
ACTION AND CLINICAL PHARMACOLOGY
......................................................... 32
STORAGE AND
STABILITY.....................................................................................
33
SPECIAL HANDLING INSTRUCTIONS
................................................................... 33
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................... 33
PART II: SCIENTIFIC
INFORMATION..........................................................................
34
CLINICAL
TRIALS....................................................................................................
35
DETAILED PHARMACOLOGY
................................................................................
38
M
                                
                                पूरा दस्तावेज़ पढ़ें
                                
                            

अन्य भाषाओं में दस्तावेज़

उत्पाद विशेषताएं उत्पाद विशेषताएं फ़्रेंच 20-10-2022

इस उत्पाद से संबंधित अलर्ट देखें

दस्तावेज़ इतिहास देखें